Last reviewed · How we verify

Bacillus Calmette-Guérin (BCG) — Competitive Intelligence Brief

Bacillus Calmette-Guérin (BCG) (Bacillus Calmette-Guérin (BCG)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine / Immunotherapy. Area: Oncology.

phase 3 Live attenuated vaccine / Immunotherapy Pattern recognition receptors (TLR2, TLR4, NOD2); non-specific immune activation Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Bacillus Calmette-Guérin (BCG) (Bacillus Calmette-Guérin (BCG)) — Memorial Sloan Kettering Cancer Center. BCG is a live attenuated mycobacterial vaccine that stimulates the immune system to recognize and destroy cancer cells, particularly in the bladder.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bacillus Calmette-Guérin (BCG) TARGET Bacillus Calmette-Guérin (BCG) Memorial Sloan Kettering Cancer Center phase 3 Live attenuated vaccine / Immunotherapy Pattern recognition receptors (TLR2, TLR4, NOD2); non-specific immune activation
Bacillus Calmette-Guerin (BCG) Bacillus Calmette-Guerin (BCG) Massachusetts General Hospital marketed Live attenuated vaccine / Immunotherapy
BCG Solution BCG Solution Alliance for Clinical Trials in Oncology marketed Live attenuated vaccine / Immunotherapy
Bacille Calmette-Guérin (BCG) Bacille Calmette-Guérin (BCG) TASK Applied Science marketed Live attenuated vaccine / Immunotherapy Pattern recognition receptors (TLR2, TLR4, NOD2); non-specific immune activation
Bacillus Calmette-Guérin Bacillus Calmette-Guérin Massachusetts General Hospital phase 3 Live attenuated vaccine / Immunotherapy
BCG for Injection BCG for Injection Suzhou Suncadia Biopharmaceuticals Co., Ltd. phase 3 Live attenuated vaccine / Immunotherapy Toll-like receptors (TLR2, TLR4); non-specific immune activation
Bacillus Calmette-Guerin: Strain TICE Bacillus Calmette-Guerin: Strain TICE Verity Pharmaceuticals Inc. phase 3 Live attenuated vaccine / Immunotherapy Pattern recognition receptors (TLR2, TLR4, NOD2); non-specific immune activation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine / Immunotherapy class)

  1. Massachusetts General Hospital · 2 drugs in this class
  2. Memorial Sloan Kettering Cancer Center · 1 drug in this class
  3. Alliance for Clinical Trials in Oncology · 1 drug in this class
  4. Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class
  5. TASK Applied Science · 1 drug in this class
  6. Verity Pharmaceuticals Inc. · 1 drug in this class
  7. Nottingham University Hospitals NHS Trust · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bacillus Calmette-Guérin (BCG) — Competitive Intelligence Brief. https://druglandscape.com/ci/bacillus-calmette-gu-rin-bcg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: